Tag - Probuphine

Feature

Titan Pharma relaunch of Probuphine paying early dividends

Titan Pharmaceuticals’ (NASDAQ:TTNP) relaunch of its Probuphine implant for the long-term maintenance treatment of opioid use disorder (OUD) demonstrated promising results with a meaningful increase in product shipments...

January 15, 2019

Developments

Molteni acquires Titan Pharma’s European Probuphine IP

Titan Pharmaceuticals (NASDAQ:TTNP) has entered into a definitive asset purchase, supply and support agreement with closely-held L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. of Italy, through which...

March 22, 2018

Tag - Probuphine

Titan Pharma relaunch of Probuphine paying early dividends

Molteni acquires Titan Pharma’s European Probuphine IP

General

More